HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• ‘Epidemic’ of cancer diagnoses attributable to better thyroid imaging
• How precise is precision medicine, anyway? Charis Eng, MD, PhD
• Breast Cancer Drugs in the Pipeline
• Choosing Wisely and the right to try (or fail) Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Dabigatran approved for DVT, PE prophylaxis after hip replacement surgery
• FDA approves Bendeka injection for CLL, non-Hodgkin’s lymphoma
• FDA approves Vistogard for overdose of certain types of chemotherapy
• FDA expands Gardasil 9 HPV vaccine approval to boys, young men
• FDA grants avelumab breakthrough therapy designation for metastatic Merkel cell carcinoma
• FDA grants orphan drug designation to ARQ 087 for cholangiocarcinoma
• FDA grants orphan drug designation to marizomib for malignant glioma
• FDA grants priority review to Ibrance for new indication in advanced breast cancer
• FDA grants priority review to Xalkori for new indication in NSCLC
• Thrombectomy catheter approved to treat DVT in peripheral veins
• ASCO endorses ASTRO recommendations for postoperative radiation in endometrial cancer
• Eliminating pretreatment biopsy reduced cost without compromising care for BCC
• KRAS variant may have prognostic role in locally advanced rectal cancer
• Many women with ovarian cancer need retreatment, regardless of initial response
• Panelists: Advances in personalized medicine must be balanced with ‘clinical reality’
• PET imaging used in about 20% of differentiated thyroid cancers
• Poor retinoblastoma outcomes associated with racial, socioeconomic factors
• Rare testicular cancer deaths may be associated with chemotherapy
• Smoking affects EGFR mutations in lung adenocarcinoma
• Study links chronic constipation in young patients with CRC, GI complications
• Targeted radiation for esophageal cancer therapy reduces toxicity without increasing recurrence
• Urine biomarkers may reduce repeat biopsies for prostate cancer
• AACR presents outstanding investigator award for breast cancer research
• ASCO elects four members to board of directors
• Association of Pediatric Hematology/Oncology Nurses elects new president
• Dana-Farber physician to serve as ASCO’s 2017-2018 president
• Fox Chase Cancer Center medical staff elects president
• Vanderbilt professor receives medal from Society of Urologic Oncology
• Anastrozole, tamoxifen associated with different symptoms in women with DCIS
• Brentuximab vedotin combinations yield encouraging response rates in elderly Hodgkin’s lymphoma
• Depression prior to HSCT linked to increased mortality, GVHD risk
• Despite advances in triplets, HSCT continues to confer benefit in multiple myeloma
• Eltrombopag increases rate of hematologic response in severe aplastic anemia
• First-line dasatinib plus pegylated-interferon alpha 2b induces deep molecular responses in CML
• Gene therapy may reduce, eliminate disease symptoms for patients with hemoglobinopathies
• Hemoglobin modifier appears safe, effective for sickle cell disease
• High-dose melphalan plus HSCT extends PFS, OS in newly diagnosed multiple myeloma
• Higher-volume facilities associated with improved survival for NHL
• Ibrutinib extends PFS in relapsed, refractory mantle cell lymphoma
• Ibrutinib, rituximab appear safe, effective for treatment-naive follicular lymphoma
• Ixazomib prolongs PFS in relapsed, refractory multiple myeloma
• Luspatercept increases hemoglobin levels, reduces transfusion burden in myelodysplastic syndromes
• Meta-analysis reveals significant interaction between HER-2 status, outcomes with aromatase inhibitors
• Network of PIK3CA mutations may affect response to HER-2–targeted therapies
• Novel flu vaccine strategy improves protection for oncology patients
• Novel treatment provides less toxic approach for pediatric HLH management
• Rituximab extends EFS in B-cell precursor ALL
• Venetoclax produces durable responses in high-risk CLL
• Reconstruction after mastectomy increases complication rates, cost
• Buparlisib plus fulvestrant extends PFS in PIK3CA-mutated, hormone receptor-positive breast cancer
• Carboplatin plus neoadjuvant chemotherapy improves DFS in triple-negative breast cancer
• Secondary breast-conserving surgery feasible for ipsilateral tumor recurrence
• Triple-negative breast cancers may differ based on BRCA1/2 status
• Wider negative margins do not improve local control in early breast cancer